Clinical use of biologics in vasculitis syndromes

Clinical use of biologics in vasculitis syndromes

Marino ParoliDivision of Clinical Immunology and Rheumatology, Department of Biotechnology and Medical-Surgical Sciences, Sapienza University of Rome, ItalyAbstract: Vasculitis syndromes are relative rare conditions but can cause significant mortality and morbidity if not treated adequately. Recent...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Paroli M
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/d0c28024be8f4a98854a4ca5b5bbc19a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d0c28024be8f4a98854a4ca5b5bbc19a
record_format dspace
spelling oai:doaj.org-article:d0c28024be8f4a98854a4ca5b5bbc19a2021-12-02T01:47:40ZClinical use of biologics in vasculitis syndromes1177-54751177-5491https://doaj.org/article/d0c28024be8f4a98854a4ca5b5bbc19a2012-10-01T00:00:00Zhttp://www.dovepress.com/clinical-use-of-biologics-in-vasculitis-syndromes-a11360https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Marino ParoliDivision of Clinical Immunology and Rheumatology, Department of Biotechnology and Medical-Surgical Sciences, Sapienza University of Rome, ItalyAbstract: Vasculitis syndromes are relative rare conditions but can cause significant mortality and morbidity if not treated adequately. Recent advances in immunosuppressant therapy have radically changed the course of these diseases. However, the standard therapy is not always well tolerated by patients, and some cases are refractory to treatment. New therapeutic possibilities have emerged with the use of so-called "biologics," a new class of genetically engineered drugs used for inflammatory rheumatic diseases, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In the present review, summarized are the most recent data on the efficacy and safety of biologics in the treatment of vasculitis syndromes that cannot be treated with standard therapy.Keywords: anti-TNF-alpha, rituximab, tocilizumab, vasculitidesParoli MDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 371-378 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Paroli M
Clinical use of biologics in vasculitis syndromes
description Marino ParoliDivision of Clinical Immunology and Rheumatology, Department of Biotechnology and Medical-Surgical Sciences, Sapienza University of Rome, ItalyAbstract: Vasculitis syndromes are relative rare conditions but can cause significant mortality and morbidity if not treated adequately. Recent advances in immunosuppressant therapy have radically changed the course of these diseases. However, the standard therapy is not always well tolerated by patients, and some cases are refractory to treatment. New therapeutic possibilities have emerged with the use of so-called "biologics," a new class of genetically engineered drugs used for inflammatory rheumatic diseases, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In the present review, summarized are the most recent data on the efficacy and safety of biologics in the treatment of vasculitis syndromes that cannot be treated with standard therapy.Keywords: anti-TNF-alpha, rituximab, tocilizumab, vasculitides
format article
author Paroli M
author_facet Paroli M
author_sort Paroli M
title Clinical use of biologics in vasculitis syndromes
title_short Clinical use of biologics in vasculitis syndromes
title_full Clinical use of biologics in vasculitis syndromes
title_fullStr Clinical use of biologics in vasculitis syndromes
title_full_unstemmed Clinical use of biologics in vasculitis syndromes
title_sort clinical use of biologics in vasculitis syndromes
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/d0c28024be8f4a98854a4ca5b5bbc19a
work_keys_str_mv AT parolim clinicaluseofbiologicsinvasculitissyndromes
_version_ 1718402925466746880

Ejemplares similares